person

Laure M.

Country
France
Department
Service de neurologie

Research Overview

Data & Insights

medical_services
Primary Speciality
Main therapeutic area

handshake
Return Partnerships
Recurring site collaborations
203
Sites with multiple studies

Has run more than one trial at 203 of 414 partner sites.

Specializations

Multiple Sclerosis Treatment

This investigator specializes in treating both relapsing and progressive forms of multiple sclerosis, with particular emphasis on innovative therapeutic approaches. Their research encompasses the evaluation of various treatment modalities including anti-CD20 therapies and novel interventions.

  • Relapsing Multiple Sclerosis (RMS)
  • Progressive Multiple Sclerosis (PMS)
  • Treatment De-escalation Strategies

Their work includes investigating breast milk concentration of MS medications in lactating patients and evaluating remyelinating therapeutic potential.

Neurological Innovations

The investigator focuses on developing and assessing novel therapeutic compounds for neurological conditions. Their research includes evaluation of Bruton's Tyrosine Kinase inhibitors and mesenchymal stromal cell treatments.

  • Cellular Kinetics Studies
  • Neuroprotective Treatments
  • Long-term Safety Assessments

Their work extends to investigating therapeutic options for patients with breakthrough disease activity.

Clinical Trial Design

The investigator demonstrates expertise in conducting complex clinical trials focusing on comparative effectiveness of treatments. Their research incorporates non-inferiority studies and long-term safety evaluations.

  • Randomized Controlled Trials
  • Safety and Efficacy Studies
  • Treatment Optimization Research

Their work includes evaluation of treatment discontinuation strategies in specific patient populations.

Related Investigators

Researchers in similar fields or departments

Want to know more about this investigator?

We can share extended profile information and contact details.

Is something out of date?

Tell us what needs correcting and we'll update this profile.